Phyllis August is a Nephrology physician affiliated with Weill Cornell Medicine. OpenAlex indexes 182 publications with 6,450 citations (h-index 42); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 E 69th St
New York, NY 100215676
Telephone
212-746-2210Registry record last updated 10 Nov 2011.
Clinical trials
- Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
Sponsor: Weill Cornell Medical College in Qatar
Overall officialPhase 2/PHASE3TerminatedNCT02410005 - Treatment Targets for Chronic Hypertension in Pregnancy
Sponsor: Weill Medical College of Cornell University
Overall officialPhase 1/PHASE2WithdrawnNCT00194974 - Hypertensive and Normal Pregnancy--Calcium Metabolism and Renin-Angiotensin - SCOR in Hypertension
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Overall officialCompletedNCT00005456
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year20258 payments$32,431openpaymentsdata.cms.gov ↗
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20257 payments
- IDORSIA PHARMACEUTICALS US INCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
89.4%Statin26.9%Atorvastatin Calcium84%Rosuvastatin Calcium16%Part D<11 patientsAldosterone antagonist (MRA)18.7%Eplerenone68%Spironolactone32%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
6.4%Biguanide (metformin)6.4%Metformin Hcl100%Part D<11 patientsNervous system
4.2%Benzodiazepine4.2%Alprazolam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1993–2004 per NIH RePORTER. The latest:
- TGF-BETA1, RENAL DISEASE AND HYPERTENSION
Weill Medical College of Cornell Univ
FY2004$114,750K24HL004268 - TGF-beta-1 and excess renal disease in African Americans
Weill Medical College of Cornell Univ
FY2004$26,378M01RR000047 - TGF-BETA1, RENAL DISEASE AND HYPERTENSION
Weill Medical College of Cornell Univ
FY2003$114,750K24HL004268
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Annals of Internal Medicine
2023 - Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
European Heart Journal - Cardiovascular Pharmacotherapy
2023 - Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
JAMA Internal Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Jedd Wolchok, MD
Weill Cornell Medicine
Richard Devereux, MD
Weill Cornell Medicine
Ronald Crystal, MD
Weill Cornell Medicine
Robert Harrington, MD
Weill Cornell Medicine
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”